Biotechnology company Prometheus Biosciences has entered a definitive agreement with Merck, a multinational pharmaceutical company, in which the latter, through a subsidiary, will acquire Prometheus for a total cash consideration of USD 10.8 billion or USD 200 per share.
The acquisition by Merck is expected to help expand its portfolio in immunology and will give Merck access to Prometheus' technology and expertise in precision medicine.
The transaction is subject to Prometheus Biosciences' shareholder approval and other regulatory conditions, and is expected to close in Q3 2023.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.